RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends

Vincendeau, S., Jiang, S., Corman, S., Kebede, N., Gnanasakthy, K., Macahilig, C., Waldeck, R., Scailteux, LM., & Hussain, A. (2022). Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends. Journal of Clinical Oncology, 6(15), 1-9. Advance online publication. https://clinicsofoncology.com/COO-v6-1415.htm

Abstract

Background: This study describes the real-world frequency, management and resource use of adverse events (AEs) of special interest in non-metastatic castration-resistant prostate cancer (nmCRPC) patients receiving androgen receptor axis targeting agents (ARATs), in France.

Download/Explore
Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.